Sunday , April 28 2024
Home / Mike Norman Economics / Remdesivir Priced At More Than $3,100 For A Course Of Treatment

Remdesivir Priced At More Than $3,100 For A Course Of Treatment

Summary:
When people will pay anything.  Your money or your life?  Let the market decide.  In the United States, Gilead Sciences will charge 0 per vial for patients with private insurance, with some government programs getting a lower price. With a double-dose the first day, that comes out to ,120 for the five-day treatment course. For governments in developed countries outside the U.S., it will cost 0 per vial, or ,340 for the five-day course. How much uninsured patients would pay is still unclear. Rep. Lloyd Doggett, D-Texas, called the price "outrageous." "Without a taxpayer investment of million, this drug would have been abandoned. It would be on the scrap heap of failures," he tells NPR. "So it's the taxpayer who's really taking the risk here and ought to get the

Topics:
Mike Norman considers the following as important:

This could be interesting, too:

Lars Pålsson Syll writes I am I said

Lars Pålsson Syll writes The non-existence of economic laws

Lars Pålsson Syll writes The non-existence of economic laws

Michael Hudson writes Gaza – Civilization will Win over Barbarism

Remdesivir Priced At More Than $3,100 For A Course Of Treatment


When people will pay anything. 

Your money or your life? 

Let the market decide. 

In the United States, Gilead Sciences will charge $520 per vial for patients with private insurance, with some government programs getting a lower price. With a double-dose the first day, that comes out to $3,120 for the five-day treatment course. For governments in developed countries outside the U.S., it will cost $390 per vial, or $2,340 for the five-day course. How much uninsured patients would pay is still unclear.

Rep. Lloyd Doggett, D-Texas, called the price "outrageous."

"Without a taxpayer investment of $99 million, this drug would have been abandoned. It would be on the scrap heap of failures," he tells NPR. "So it's the taxpayer who's really taking the risk here and ought to get the reward of the angel investors that taxpayers are."

 Remdesivir, made by @GileadSciences, has now set the price ➡️ $2,300 to $3,100 per patient.
So how much does it cost to produce each vial? 
➡️ Just $1. 
US taxpayers also had paid for the drug’s NIH trial. 

NPR

Remdesivir Priced At More Than $3,100 For A Course Of Treatment-3-100-for-a-course-of-treatment

 

Mike Norman
Mike Norman is an economist and veteran trader whose career has spanned over 30 years on Wall Street. He is a former member and trader on the CME, NYMEX, COMEX and NYFE and he managed money for one of the largest hedge funds and ran a prop trading desk for Credit Suisse.

Leave a Reply

Your email address will not be published. Required fields are marked *